Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Turin – page 13

677 clinical trials in Turin, Italy across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Turin at a glance
677
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

677 trials in Turin

Open in trial search

Acromegaly

Recruiting

Study of Debio 4126, a new octreotide formulation, compared to placebo in patients with acromegaly who were previously treated with somatostatin analogs

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Debiopharm International SA

Acute myeloid leukaemia

Recruiting

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Janssen Cilag International

Follicular lymphoma

Recruiting

Study Comparing Golcadomide and Rituximab with Other Treatments for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Celgene Corp.

Neuroblastoma

Recruiting

Study of Temozolomide, Topotecan, Bevacizumab, Irinotecan and Dinutuximab Beta in Patients with High-Risk Relapsed Neuroblastoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Bevacizumab
  • Sponsor:The University Of Birmingham

Endometrial cancer

Recruiting

Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Colorectal cancer metastatic

Recruiting

Study on the Safety and Effectiveness of Telisotuzumab Adizutecan and Drug Combination for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Endometrial cancer

Recruiting

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Renal transplant+1

Recruiting

Study of Ravulizumab to Prevent Delayed Graft Function in Adult Patients After Kidney Transplant

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

IgA nephropathy

Recruiting

Study on Ravulizumab for Children with IgA Nephropathy (Ages 2-17)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Hepatoblastoma+1

Recruiting

Study on the Safety and Effectiveness of Patritumab Deruxtecan for Children with Relapsed or Refractory Hepatoblastoma and Rhabdomyosarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Dexamethasone
  • Sponsor:Merck Sharp & Dohme LLC

Chronic myelomonocytic leukaemia+1

Recruiting

Study Comparing Oral Azacitidine and Cedazuridine with Subcutaneous Azacitidine for Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Taiho Oncology Inc.

HER2 positive gastric cancer

Recruiting

Study Comparing Rilvegostomig with Fluoropyrimidine and Trastuzumab Deruxtecan to Standard Treatment for Patients with HER2-positive Gastric Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Turin

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple myeloma, colorectal cancer, and breast cancer treatments. Studies include evaluation of targeted therapies and immunotherapy approaches for various stages of disease.

  • Triple-negative breast cancer treatments
  • Advanced urothelial cancer therapy
  • Novel lymphoma interventions

Several trials are investigating combination therapies and maintenance treatments to improve patient outcomes.

02 Transplant Medicine

Research centered on improving outcomes in kidney transplantation, with particular focus on preventing delayed graft function and optimizing post-transplant care.

  • Graft function optimization
  • Novel immunosuppressive approaches
  • Post-transplant complications

Studies aim to enhance transplant success rates and reduce complications in organ recipients.

03 Autoimmune Conditions

Investigations into treatments for various autoimmune disorders, including Crohn's Disease and pyoderma gangrenosum. Studies evaluate new biological therapies and combination treatments.

  • Inflammatory bowel disease management
  • Skin condition treatments
  • Novel therapeutic combinations

Focus on developing targeted treatments to improve disease control and patient quality of life.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.